CXCR4 Inhibition Improves Donor Leukocyte Depletion During Ex Vivo Lung Perfusion

Ex vivo lung perfusion (EVLP) has emerged as a modern preservation technique developed to evaluate candidate donor lungs in a normothermic and metabolically active state. Donor leukocytes are linked to the development of transplant related ischemia reperfusion injury, primary graft dysfunction, and acute rejection. Pharmacologic strategies to enhance donor leukocyte depletion during EVLP have not yet been described. Plerixafor (Mozobil) is a clinically available CXCR4 receptor antagonist, which disrupts the interaction between CXCR4 and SDF-1 α and facilitates mobilization of hematopoietic stem cells into peripheral circulation.

Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: R. Davis, Q. Gao, J. Yerxa, M. Daneshmand, J. Haney, J. Klapper, M. Hartwig, A. Barbas. Source Type: research